Stockreport

LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update

LeonaBio, Inc.  (LONA) 
PDF Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treat [Read more]